Does orforglipron (Foundayo) cause hair loss?

Hair loss is a listed adverse reaction on the FDA-approved Foundayo label. In pooled clinical trials, it was reported more often in women (about 7%) than men (about 0.9%) taking orforglipron, versus about 3% of women and 0.7% of men on placebo. It's less common than GI side effects like nausea, but it's real and documented.

Why does a weight-loss pill cause hair loss?

Per the FDA label, hair loss reported with orforglipron was associated with weight reduction, not a direct effect of the drug on hair follicles. Rapid or significant weight loss from any cause — diet, surgery, illness, or medication — can push more hair follicles than usual into a resting (telogen) phase at once, a temporary pattern called telogen effluvium.

Is orforglipron hair loss permanent?

Telogen effluvium, the pattern typically linked to rapid weight loss, is temporary — hair follicles aren't destroyed, they're just paused. Hair usually regrows once weight stabilizes and the body's demands settle. This article is educational, not a diagnosis; a dermatologist or your prescriber can evaluate hair loss that doesn't fit that pattern or doesn't improve.

When does hair loss typically start after beginning a GLP-1 medication?

Telogen effluvium linked to weight loss generally shows up a couple of months after the triggering event — commonly cited as roughly two to four months in after significant weight loss begins — not immediately after the first dose.

Can I prevent hair loss while taking orforglipron?

There's no guaranteed way to prevent it, since it's tied to the pace of weight loss and the body's nutritional demands during that process. Getting adequate protein and overall nutrition while losing weight is commonly discussed as supportive for hair (and muscle) during any rapid weight loss. This isn't medical advice — talk to your prescriber if hair loss concerns you.

Should I stop taking orforglipron if I notice hair shedding?

Don't stop or change a GLP-1 medication on your own because of hair loss. Bring it up with your prescriber — they can assess whether it fits the expected weight-loss-related pattern, check for other causes, and weigh it against your treatment goals.

Does Orforglipron Cause Hair Loss? What the Foundayo Label Actually Says

Educational information, not medical advice. This guide is for general understanding of oral GLP-1 medicines. Always follow your prescriber's instructions and talk to a qualified clinician about your treatment.

Yes — hair loss is a listed side effect on the FDA-approved Foundayo (orforglipron) label, though it’s far less common than GI side effects like nausea. In pooled clinical trial data, it showed up more in women than men, and the label ties it to weight reduction itself rather than a direct effect of the drug on hair follicles. Here’s what the label actually documents, why weight loss triggers hair shedding, and what tends to happen next.

Does orforglipron cause hair loss? What the label reports

Per the FDA-approved FOUNDAYO label on DailyMed, hair loss was reported as an adverse reaction in clinical trials, with a clear gender split:

Group	Orforglipron	Placebo
Women	~7%	~3%
Men	~0.9%	~0.7%

The label also notes that hair loss in orforglipron-treated patients was associated with weight reduction — meaning the pattern tracks with how much and how fast someone lost weight, not with the drug acting on hair directly. That distinction matters: it’s the same kind of hair shedding reported after other rapid-weight-loss situations, not something unique to orforglipron’s mechanism.

Why rapid weight loss triggers hair shedding

The mechanism behind this is a well-documented, temporary condition called telogen effluvium. Hair grows in cycles — an active growth phase followed by a resting phase, after which the hair sheds and a new one grows in. A significant physical stressor — rapid weight loss, a major illness, surgery, or a big calorie deficit — can push a larger-than-usual share of hair follicles into that resting phase all at once. A few months later, more hair than normal sheds during the ordinary cycle, which reads as noticeable thinning.

This isn’t unique to orforglipron. It’s a recognized pattern with GLP-1 medications generally, tied to the amount and speed of weight loss rather than to any one drug’s chemistry — which is consistent with why the Foundayo label frames it as associated with weight reduction rather than as a direct pharmacologic effect. Hair shedding has been reported anecdotally with other GLP-1 medications too, including injectable semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound); patients and prescribers using MedlinePlus drug information for those medications should ask about it the same way. If you’re weighing orforglipron against an injectable GLP-1, our orforglipron vs Ozempic comparison covers other side-effect and mechanism differences between the oral and injectable options.

Who’s more likely to notice it

The Foundayo trial data points to two risk factors. First, sex — hair loss was reported at roughly 8x the rate in women (about 7%) compared to men (about 0.9%) taking orforglipron, a pattern that also shows up in the placebo group (about 3% women versus 0.7% men), suggesting women may simply be more likely to notice or report hair shedding regardless of cause. Second, how much weight is lost and how fast — because the label associates hair loss with weight reduction itself, people who lose weight quickly or lose a larger amount are, in principle, more likely to experience the telogen-effluvium pattern than someone losing weight gradually. Neither factor is something to be alarmed by; they’re just useful context for who tends to report it.

Timeline: when it tends to show up

Telogen effluvium doesn’t happen immediately. It typically follows the triggering stressor by a couple of months — commonly discussed as roughly two to four months after a period of significant weight loss begins, not right after starting the medication. That lag is part of why it can catch people off guard: by the time hair shedding is noticeable, someone may have already been on a stable dose for a while and not immediately connect the two.

Is it reversible?

Telogen effluvium is, by definition, a temporary shift in the hair growth cycle — the follicles themselves aren’t destroyed. For most people, hair density recovers once weight stabilizes and nutritional intake catches up with the body’s needs. It’s not an instant bounce-back; regrowth happens on the same slow timeline hair normally grows on, so it can take several months to look and feel back to normal.

What might help, and what to actually do

None of this is medical advice, but a few things are commonly discussed in the context of weight-loss-related hair shedding:

Adequate protein and overall nutrition. Hair follicles need a steady supply of nutrients, and a sharply reduced appetite (part of how GLP-1s work) can mean lower intake of protein, iron, and other nutrients that support hair, even while calorie intake is technically “enough.” Our protein on GLP-1s guide covers practical ways to hit a protein target on a smaller appetite — the same habits that help protect muscle during GLP-1-driven weight loss are relevant here too, since both are downstream of nutrition during rapid weight loss (see GLP-1s and muscle loss).
Not rushing the titration. Slower weight loss generally means a gentler physiological stressor. If you’re on the standard Foundayo titration schedule, that gradual dose ramp is already working somewhat in your favor here, separate from its role in easing GI side effects.
Talking to your prescriber, not guessing. Hair loss has plenty of causes besides weight-loss-related telogen effluvium — thyroid issues, iron deficiency, and other conditions can look similar. Your prescriber or a dermatologist can rule those out and confirm whether what you’re seeing fits the expected pattern.

Don’t stop or adjust orforglipron on your own because of hair shedding. It’s worth flagging to your prescriber, both to check for other causes and so they can weigh it against how the medication is working for you overall. For the fuller picture of what to expect on orforglipron, see our orforglipron side effects guide.

Bottom line

Hair loss is a real, FDA-label-documented side effect of orforglipron — more common in women (about 7%) than men (about 0.9%) in trials, versus roughly 3% and 0.7% on placebo — and it tracks with weight reduction rather than being a direct drug effect. The pattern is consistent with telogen effluvium, a temporary, well-understood response to rapid weight loss that typically shows up a couple of months in and resolves as weight stabilizes. If it’s happening to you, it’s a reasonable, normal thing to bring up with your prescriber — not a reason to stop treatment on your own.